menu
    • menu
    [{"orgOrder":0,"company":"DeFloria","sponsor":"AJNA BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"AJA001","moa":"CB receptor","graph1":"Neurology","graph2":"Phase I","graph3":"DeFloria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"DeFloria \/ AJNA BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"DeFloria \/ AJNA BioSciences"},{"orgOrder":0,"company":"DeFloria","sponsor":"AJNA BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"AJA001","moa":"CB receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DeFloria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"DeFloria \/ AJNA BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"DeFloria \/ AJNA BioSciences"}]

    Find Clinical Drug Pipeline Developments & Deals by DeFloria

    Menu

    DeFloria

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DeFloria

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            DeFloria

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AJA001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : AJNA BioSciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DeFloria Receives IND Clearance from FDA for Phase 2 of AJA001 for ASD

                            Details : AJA001 is an investigational full-spectrum cannabinoid drug, it leverages Charlotte's Web's proprietary hemp genetics. It is being evaluated for autism spectrum disorder.

                            Product Name : AJA001

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 24, 2025

                            Lead Product(s) : AJA001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : AJNA BioSciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DeFloria

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            DeFloria

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AJA001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : AJNA BioSciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DeFloria LLC Commences Phase 1 Clinical Program for Innovative Full Spectrum Hemp Botanical Drug

                            Details : AJA001 is an investigational full-spectrum cannabinoid drug, it leverages Charlotte's Web's proprietary hemp genetics. It is under phase 1 clinical development for the treatment of neurological & mental health disorders.

                            Product Name : AJA001

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            December 13, 2023

                            Lead Product(s) : AJA001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : AJNA BioSciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth